|
POLYRIZON, LTD .
NASDAQ: PLRZ
Last Price: 14.68 | Website | Latest News
Ggg, if you missed last nights' alert on PLRZ make sure your read below. We are talking about a unique situation with a NASDAQ play in the early stages that could revolutionize the way we treat seasonable allergies.
Third-party research estimates that the global allergic rhinitis market could reach $16.28 BILLION in 2026 and $19.58 BILLION by 2030.
CDC data show that 25.2% of U.S. adults had a diagnosed seasonal allergy in 2024. And 20.6% of U.S. children were also reported to have a seasonal allergy.
We are talking about an utterly MASSIVE market.
So, when we uncover an Under-Followed stock that could be at the forefront of the next BIG step forward in treating seasonal allergies, we take notice BEFORE everyone else.
WE ARE ISSUING AN IMMEDIATE ALERT ON PLRZ
Polyrizon Ltd. (PLRZ), a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; and PL-16 for influenza blockers.
On June 8, the company announced that it had contracted THREE U.S. CLINICAL SITES for its planned NASARIX™ study in seasonal allergic rhinitis.
Then came CENTRAL IRB APPROVAL for the study protocol, patient-consent forms and trial materials.
On July 2, Polyrizon reported that all required NASARIX™ biological safety tests met their predetermined acceptance criteria.
The stock finished July 24 at $14.68 after trading as high as $15.58 as it appears to be inching its' way back towards it's 52-Week High of 18.20
But the transition from preparation toward treating actual patients is where early-stage biotech stories can go mainstream...
A DRUG-FREE ALLERGY BARRIER BUILT FOR THE POINT OF ENTRY
NASARIX™ is an investigational, drug-free mucoadhesive nasal spray intended to create a physical barrier that helps reduce exposure to airborne allergens associated with seasonal allergic rhinitis.
The approved study is designed to evaluate NASARIX™ against saline spray for efficacy, safety and tolerability in patients with seasonal allergic rhinitis.
In other words, this is not another pill designed to work after an allergen enters the body. The breakthrough idea is to meet airborne allergens at the front door - the nasal cavity - and form a protective barrier before exposure progresses.
Behind NASARIX™, Polyrizon is also developing its earlier-stage Trap & Target™ platform for the intranasal delivery of active pharmaceutical ingredients.
COULD $15.91 BE THE GATE TO ANOTHER TEST OF THE HIGHS?
PLRZ advanced for three consecutive sessions from July 21 through July 23, climbing from $13.49 to $15.31.
The stocks' recent pulled back 4.11% on July 24 but still ended the five-session period up approximately 8.8%.
As you can see from the chart above, is the start of this recent rally a BREAKOUT point? With RSI trending up and now nearing the POWER ZONE - this may be just the start for PLRZ.
The stock’s 52-week high stands at $18.20, a move back to this level would imply nearly 24% UPSIDE.
But could a sustained move put PLRZ on track to print a NEW 52-Week High?
NEWS CATALYSTS TO KNOW RIGHT NOW
✔ Three U.S. clinical sites contracted for the planned NASARIX™ study
Why it matters: the company is moving from clinical planning toward the infrastructure needed to recruit and evaluate patients.
✔ Central IRB approval for the protocol and study materials
Why it matters: a central ethics review is a documented clinical operations milestone, although site-specific approvals are still required.
✔ NASARIX™ biocompatibility testing met stated acceptance criteria
Why it matters: the company says the results support the product’s nonclinical package as it advances toward first-in-human testing.
✔ European patent publication involving the Trap & Target™ platform
Why it matters: the platform gives Polyrizon a second technology angle beyond the immediate NASARIX™ clinical program.
✔ THE NEXT CHECKPOINT: Individual site approvals and the company’s progress toward patient enrollment remain key items for traders to monitor.
THE BOTTOM LINE
Subscriber, let’s recap what we have here...
A Nasdaq-listed biotech targeting an allergic rhinitis market estimated at more than $16 BILLION in 2026.
Three contracted U.S. clinical sites. Central IRB approval. And a completed biocompatibility program that met the company’s stated criteria.
YET this remains an early-stage clinical story. That is precisely why PLRZ is a SITUATION that demands your attention today.
For traders hunting small-cap biotech newsflow with momentum building...
PLRZ DESERVES A SPOT ON THE RADAR.
Make sure you put it on your screen RIGHT NOW and Follow on Twitter for Updates + Play-by-Play!
|
